(NASDAQ: VSTM) Verastem's forecast annual revenue growth rate of 168.5% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Verastem's revenue in 2025 is $10,000,000.On average, 3 Wall Street analysts forecast VSTM's revenue for 2025 to be $1,062,332,304, with the lowest VSTM revenue forecast at $939,630,807, and the highest VSTM revenue forecast at $1,126,457,985. On average, 4 Wall Street analysts forecast VSTM's revenue for 2026 to be $5,622,508,973, with the lowest VSTM revenue forecast at $4,328,346,121, and the highest VSTM revenue forecast at $6,666,433,304.
In 2027, VSTM is forecast to generate $10,721,407,305 in revenue, with the lowest revenue forecast at $8,589,654,254 and the highest revenue forecast at $13,503,209,036.